CDK8 and colorectal cancer: In colorectal cancer cells, impairing glucose transporter expression, glucose uptake, and glycolytic capacity in both normoxia and hypoxia can be achieved by using the CDK8/CDK19 inhibitor Senexin A or through the knockdown of CDK8.